Nuveen’s Mineralys Therapeutics MLYS Stock Holding History

Nuveen’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.03M	Sell	112,007 -10,940	-9%	-$321K	﹤0.01%	2103
2025 Q4	$4.46M	Buy	122,947 +36,031	+41%	+$1.44M	﹤0.01%	1959
2025 Q3	$3.3M	Buy	86,916 +9,269	+12%	+$200K	﹤0.01%	2102
2025 Q2	$1.05M	Buy	77,647 +9,770	+14%	+$142K	﹤0.01%	2581
2025 Q1	$1.08M	Hold	67,877	–	–	﹤0.01%	2616
2024 Q4	$836K	Hold	67,877	–	–	﹤0.01%	2786
2024 Q3	$822K	Buy	67,877 +1,248	+2%	+$15.1K	﹤0.01%	2840
2024 Q2	$780K	Buy	66,629 +31,798	+91%	+$400K	﹤0.01%	2839
2024 Q1	$450K	Hold	34,831	–	–	﹤0.01%	3008
2023 Q4	$300K	Buy	34,831 +15,676	+82%	+$123K	﹤0.01%	3147
2023 Q3	$182K	Hold	19,155	–	–	﹤0.01%	3052
2023 Q2	$327K	Buy	19,155 +3,021	+19%	+$45.2K	﹤0.01%	3002
2023 Q1	$253K	Buy	+16,134	New	+$272K	﹤0.01%	2945

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Nuveen's MLYS Position: Q1 2026 in Review

Nuveen reduced its Mineralys Therapeutics (MLYS) stake by 8.9% in Q1 2026, selling an estimated $321K and leaving 112,007 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2103.

Nuveen first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $4.46M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Nuveen held 112,007 shares of Mineralys Therapeutics worth $3.03M as of Q1 2026.
Nuveen sold 10,940 Mineralys Therapeutics shares in Q1 2026, an estimated $321K.
Mineralys Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2103 holding.
Nuveen first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
Nuveen's Mineralys Therapeutics position peaked at $4.46M in Q4 2025.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.